NEW YORK, Sept. 20 - Proteome Systems of Sydney and Protagen of Bochum, Germany, have announced that they would share their technologies for analyzing the post-translational modifications of proteins to better understand the role proteins play in disease.
Under the terms of the deal, Proteome Systems will have access to Protagen’s technology for analyzing protein phosphorylation. In exchange, Protagen will have access to Proteome’s technology for analyzing glycosylation. Phosphorylation and glycosylation are two modification types.
"Being able to identify a protein is one thing, being able to understand its post-translational modifications and their relationship to disease is a much greater challenge,” Nicolle Packer, executive vice president of biomolecular analysis at Proteome Systems, said in a statement. “An understanding of phosphorylation on proteins gives important insights into the activity state of a protein.”
Helmut Meyer, Protagen’s chief scientific officer said: "Glycosylation has a crucial role in protein structure and activity. There is good evidence of altered glycosylation states on proteins in various disease states.”
As part of the collaboration Keith Williams, CEO of Proteome Systems will join Protagen’s scientific advisory board and Meyer will join Proteome’s scientific board.